01_CANbridge_Logo_1

CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS CANbridge to Hold Investor Call BEIJING...